India, Nov. 1 -- The minimal residual disease (MRD) testing market, one of the fastest-growing segments of the global diagnostics industry, has reached an inflection point. The defining question is no longer who has the most sensitive assay, but where and how cancer monitoring will be delivered.

As oncology moves toward precision treatment, recurrence monitoring, and therapy optimisation, MRD is shifting from a niche diagnostic tool to a core component of longitudinal cancer care. By detecting molecular evidence of disease before clinical relapse, it is changing how clinicians evaluate treatment response, stratify risk, and determine when to intervene across the patient journey.

Two competing models are taking shape: the centralised meg...